| Business Summary | | Kosan
Biosciences,
Inc.
is
a
biotechnology
company
that
uses
its
proprietary
technologies
to
develop
drug
candidates
from
a
class
of
natural
product
compounds
known
as
polyketides.
Polyketides
are
found
in
very
small
amounts
in
microorganisms
and
are
difficult
to
make
or
modify
chemically.
The
Company's
proprietary
technologies
are
designed
to
create,
modify
and
produce
polyketides
in
ways
that
chemists
cannot.
The
Company's
technology
platform
has
five
components:
polyketide
gene
alteration,
chemo-biosynthesis,
heterologous
over-expression,
combinatorial
biosynthesis
and
screening
libraries.
Together,
its
technologies
enable
Kosan
to
modify,
create
and
produce
proprietary
polyketides
with
potential
for
development
as
valuable
pharmaceutical
products. | More
from
Market Guide: Expanded
Business Description |
| Financial Summary | | KOSN
is
a
biotechnology
company
using
proprietary
technologies
to
develop
drug
candidates
from
an
important
class
of
natural
product
compounds
known
as
polyketides.
For
the
six
months
ended
6/30/01,
revenues
fell
1%
to
$2.2
million.
Net
loss
applicable
to
Common
fell
39%
to
$10.9
million.
Revenues
reflect
a
decrease
in
contract
sales
attributable
to
the
absence
of
an
up-front
fee
received
in
2000.
Lower
loss
reflects
the
absence
of
$11.3
million
in
preferred
dividends. | More
from
Market Guide: Significant
Developments |
| | | | FY2000
Compensation | | Pay | Exer | |
| Daniel Santi, M.D., Ph.D., 59 Chairman,
CEO | $318K | -- | Susan Kanaya, 38 CFO,
VP-Fin. | 203K | $45K | Michael Ostrach, 49 Sr.
VP, COO | 264K | 36K | Brian Metcalf, Ph.D., 55 Sr.
VP, CSO | 409K | -- | Robert Johnson, Jr., M.D., Ph.D., 49 VP,
Medical Affairs and Corp. Devel. | -- | -- | Dollar
amounts are as of 31-Dec-2000 and compensation values are for the fiscal year ending on that date; "Pay" is salary, bonuses, etc.; "Exer" is the value of options excercised during the fiscal year. |
| More
from
Market Guide on Officers & Directors: Expanded
List, Bios,
Compensation,
Options
|
|